glp 1 agonist benefits GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies In patients with #obesity, incretin-based
Description
Recent advances in the understanding of the pathophysiology of preeclampsia
It's released when you eat and tells your body to make insulin to control your blood sugar
Both drugs are delivered via subcutaneous (beneath the skin) injection using autoinjectors (patients can self-administer the injection at home)
Fixed-dose combinations could optimize outcomes, particularly for patients with advanced disease or those unresponsive to monotherapy
doi: 10.1210/en.2012-1983 [DOI] [PubMed] [Google Scholar] 137
